Photonic hyperthermal and sonodynamic nanotherapy targeting oral squamous cell carcinoma
Jiaxin Zuo1, Minfeng Huo2, Liying Wang2
1Department of Ultrasound, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200011, P. R. China. xiongp1281@sh9hospital.org.cn.
Abstract:
Nanomedicine that enables multiple synergetic treatments provides effective non-invasive treatment modalities for cancer therapy. Yet treatments for oral squamous cell carcinoma (OSCC) are rarely reported. Here, we designed OSCC-targeting multi-functional nanomedicines to overcome the therapeutic obstacles during OSCC treatments, including ineffective chemotherapy, and the traumatic surgery and radiotherapy. The urokinase plasminogen activator receptor (uPAR)-targeting ligand AE105 decorated dendritic mesoporous silica nanoparticles (DMSN) encapsulating photonic active ultrasmall Cu2-xS NPs and sonosensitizer Rose Bengal (RB) have been rationally designed and constructed (designated as Cu2-xS-RB@DMSN-AE105, abbreviated as CRDA). These CRDAs initially target the uPAR, which is overexpressed in the OSCC cell membrane, to increase the localized accumulation of CRDAs at tumor sites. Under the irradiation of both near-infrared laser and ultrasound, the in situ photonic-hyperthermal and sonodynamic effects are respectively enabled to induce the cell death of OSCC. Upon both in vitro/in vivo challenges, tumor cells/xenografts have been efficiently eradicated, achieving the targeting and synergetic treatment modality against the OSCC with satisfactory biocompatibility.
Insights
New nanomedicine targets oral cancer (OSCC) using combined light and ultrasound therapy. This approach effectively eliminates tumor cells non-invasively, offering a promising alternative to traditional treatments.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Oral squamous cell carcinoma (OSCC) treatment remains challenging, often involving invasive surgery or radiotherapy.
- Current nanomedicine approaches for OSCC are limited, necessitating novel therapeutic strategies.
Purpose of the Study:
- To design and develop multifunctional nanomedicines for targeted OSCC therapy.
- To overcome limitations of conventional OSCC treatments like ineffective chemotherapy and traumatic interventions.
Main Methods:
- Engineered dendritic mesoporous silica nanoparticles (DMSN) decorated with uPAR-targeting ligand AE105.
- Encapsulated ultrasmall copper sulfide nanoparticles (Cu2-xS NPs) for photothermal therapy and Rose Bengal (RB) as a sonosensitizer.
- Designated as Cu2-xS-RB@DMSN-AE105 (CRDA), targeting uPAR-overexpressed OSCC cells.
Main Results:
- CRDAs demonstrated targeted accumulation at OSCC tumor sites due to uPAR targeting.
- Combined near-infrared laser and ultrasound irradiation induced synergistic photothermal and sonodynamic effects.
- Efficient eradication of OSCC cells and xenografts in vitro and in vivo was achieved.
Conclusions:
- The developed CRDA nanomedicine offers a non-invasive, targeted, and synergistic treatment modality for OSCC.
- This approach shows significant potential for improving OSCC therapy with satisfactory biocompatibility.
More Related Videos
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...